Triazolopyridine PDE4 Inhibitors Isoform Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for inflammatory diseases lack specificity for PDE4 isoforms, leading to adverse effects such as nausea and emesis, and existing compounds like theophylline have severe side effects, limiting their clinical utility.
Innovation Solution
Development of novel compounds without a carbonyl linker between ring systems that exhibit PDE4 inhibitory activity, offering a potential therapeutic option for inflammatory and allergic diseases without the adverse effects associated with existing PDE4 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PDE4 inhibitors (e.g., theophylline, rolipram) are used to treat inflammatory diseases, then PDE4 inhibitory activity is achieved, but adverse effects such as nausea, emesis, arrhythmia, and convulsions occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns at defined positions on the triazolopyridine core structure. Different substituents (R1-R6) are placed at specific locations to achieve selective interaction with PDE4 isoforms, particularly PDE4D, while minimizing off-target effects that cause adverse reactions.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, and ring structures in the triazolopyridine compounds. This allows optimization of the balance between PDE4 inhibitory potency and selectivity, reducing adverse effects while maintaining therapeutic efficacy.
2Reliability
If non-selective PDE4 inhibitors are used, then broad PDE4 inhibition is achieved, but specificity for particular PDE4 isoforms is lost leading to increased side effects
Solution Approach 1:
The patent achieves isoform specificity through local quality by introducing specific substituent patterns at defined positions on the triazolopyridine core. These localized chemical features enable selective binding to particular PDE4 isoforms (especially PDE4D) while maintaining inhibitory efficacy, thus resolving the contradiction between broad inhibition and precise isoform targeting.
Solution Approach 2:
The patent applies asymmetry by designing compounds with asymmetric substituent arrangements on the triazolopyridine core. This asymmetric structure allows differential interaction with specific PDE4 isoforms, enhancing selectivity while maintaining overall inhibitory activity against the PDE4 enzyme family.
Data Source
AI summary
The present invention relates to a compound according to formula I, wherein R1, R2 and A are as defined herein, which exhibit PDE4 inhibitory activity and may be used in the treatment of inflammatory diseases or autoimmune diseases, in particular inflammatory or proliferative dermal diseases.